Expansion into medical aesthetics and regenerative medicine through the acquisition of クレマンスラボラトリー
First written in FY2022-Q3. 4 of 9 entries say "Restated". Latest entry: FY2025.
No other company in this theme has enough history to compare yet.
- FY2025WorsenedAnnual report
「The Company will continue to make active business investments toward monetization of the Medical Marketing field, which began full-scale operations in the previous consolidated fiscal year.」
It is stated that, although the Medical Marketing field began full-scale operations in the previous fiscal year, monetization remains an issue and active business investment will continue. - FY2024-Q3RestatedAnnual report
「Because additional transactions, including loans of funds, occurred and the Company came to have control, 一般社団法人涼香会 was changed from an equity-method associate to a consolidated subsidiary.」
It has been reconfirmed that 一般社団法人涼香会 became a consolidated subsidiary through additional loans of funds and other transactions. - FY2024-Q2RestatedAnnual report
「Because additional transactions, including loans of funds, occurred and the Company came to have control, 一般社団法人涼香会 was changed from an equity-method associate to a consolidated subsidiary.」
It has been reconfirmed that 一般社団法人涼香会 became a consolidated subsidiary through additional loans of funds and other transactions. - FY2024-Q1AdvancedAnnual report
「(Medical Marketing field) Because additional transactions, including loans of funds, occurred and the Company came to have control, 一般社団法人涼香会 was changed from an equity-method associate to a consolidated subsidiary.」
With respect to 一般社団法人涼香会, which is associated with the Medical Marketing field, the Company gained control through additional loans of funds and other transactions, and it changed from an equity-method associate to a consolidated subsidiary. - FY2023ReframedAnnual report
「From the fiscal year ending March 2024, we will work toward monetizing the Medical Marketing field.」
The former Medical Beauty field was reorganized in name and positioning as the Medical Marketing field, with a stated policy of pursuing monetization from the fiscal year ending March 2024. - FY2023-Q3RestatedAnnual report
「<Medical beauty field> Development and sale of products sold exclusively through aesthetic clinics, and comprehensive production and operational support for clinics」
It has been reconfirmed that the Medical Beauty field involves developing and selling products sold exclusively through aesthetic clinics, as well as providing comprehensive production and operational support for clinics. - FY2023-Q1RestatedAnnual report
「<Medical beauty field> Development and sale of products sold exclusively through aesthetic clinics, and comprehensive production and operational support for clinics」
It has been reconfirmed that the Medical Beauty field involves developing and selling products sold exclusively through aesthetic clinics, as well as providing comprehensive production and operational support for clinics. - FY2022AdvancedAnnual report
「As of the filing date, the Group comprises the Company and its consolidated subsidiary 株式会社クレマンスラボラトリー and operates two businesses: the Marketing Business and the Investment Business. The Marketing Business comprises three areas: the Marketing Solutions area, the Brand and Media Development area and the Medical Beauty area.」
Following クレマンスラボラトリー’s incorporation as a consolidated subsidiary, the medical beauty field, based on its expertise in medical aesthetics and regenerative medicine, was incorporated as one of the 3 formal fields of the Marketing business. - FY2022-Q3First statedAnnual report
「At a meeting of the Board of Directors held on 24 December 2021, the Company resolved to carry out a share delivery in which the Company would be the parent company receiving the shares and 株式会社クレマンスラボラトリー (hereinafter, “クレマンスラボラトリー”) would be the subsidiary company delivering the shares. The Company acquired the shares of the company on 7 February 2022, making it a consolidated subsidiary. The objective is to enhance the value of the Group and address industry issues by combining クレマンスラボラトリー’s expertise in medical aesthetics and regenerative medicine with the Company’s marketing expertise, and engaging in DX support and marketing support in the medical aesthetics and regenerative medicine fields, as well as medical procedures, formulations and exclusive products.」
Following the Board of Directors’ resolution, クレマンスラボラトリー became a consolidated subsidiary with a 100% voting-rights ratio through a share delivery. The consideration consisted of ¥21.650 million in cash and ¥8.350 million in the Company’s shares, with plans to expand into DX support, marketing support, medical procedures, formulations and exclusive products by combining expertise in medical aesthetics and regenerative medicine with marketing expertise.